research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
Search
for
Sort by
Research
570-600 / 1000+ results 
research Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis
Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Case Report: Pulsed electric field treatment of metastatic liver disease demonstrating a possible abscopal response
Pulsed electric field treatment may help the immune system fight liver tumors.
research The effects of hair regrowth with intravenous immunoglobulin (IVIG) therapy. Two case reports
IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.
research Cyproterone is effective for androgenetic alopecia in women
Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.
research Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research Treatment of Lipodystrophy with Troglitazone
Troglitazone increases subcutaneous fat in lipodystrophy patients.
research Candida antigen immunotherapy versus steroid in the treatment of alopecia areata
Candida antigen is an effective and promising treatment for alopecia areata.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Peptichemio: A New Oncolytic Drug in Combination with Vincristine and Prednisolone in the Treatment of Non-Hodgkin Lymphomas
The treatment was effective for advanced non-Hodgkin's lymphomas.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
JAK inhibitors are effective and safe for treating severe alopecia areata.
research Parenteral and Oral Cyproterone Acetate Treatment in Severe Hirsutism
Cyproterone acetate implants were more effective at reducing facial hair and improving skin in severe hirsutism than oral treatment.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir
A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
research A COMPARATIVE CLINICAL STUDY OF INTRALESIONAL PLATELET-RICH PLASMA AND INTRALESIONAL CORTICOSTEROID IN MANAGING ALOPECIA AREATA : EFFICACY AND PATIENT ACCEPTIBILITY
PRP is a promising alternative for alopecia areata due to its safety and patient satisfaction.
research Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse
Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
research Injectable Platelet-, Leukocyte-, and Fibrin-Rich Plasma (iL-PRF) in the Management of Androgenetic Alopecia
iL-PRF treatment improves hair growth for androgenetic alopecia.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.